136476-38-5

Basic information

• Product Name: 1,1-CyclopropanediMethanol diMethanesulfonate
• Synonyms: 1,1-CyclopropanediMethanol diMethanesulfonate;1,1-Cyclopropanedimethanol 1,1-dimethanesulfonate;CYCLOPROPANE-1,1-DIYLBIS(METHYLENE) DIMETHANESULFONATE
• CAS NO: 136476-38-5
• Molecular Formula: C₇H₁₄O₆S₂
• Molecular Weight: 258.31246
• Mol File: 136476-38-5.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 463.0±18.0 °C(Predicted)
• Appearance: /
• Density: 1.422±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1,1-CyclopropanediMethanol diMethanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 1,1-CyclopropanediMethanol diMethanesulfonate(136476-38-5)
• EPA Substance Registry System: 1,1-CyclopropanediMethanol diMethanesulfonate(136476-38-5)

Safety Data

• Hazardous Substances Data: 136476-38-5(Hazardous Substances Data)

Usage

General Description

1,1-CyclopropanediMethanol diMethanesulfonate is a chemical compound that is used in organic synthesis as a reagent and intermediate. It is a derivative of cyclopropane and contains two methanesulfonate groups. 1,1-CyclopropanediMethanol diMethanesulfonate is often used in the preparation of cyclopropane derivatives and in the synthesis of various organic compounds. It is also used as a reagent in the production of pharmaceuticals and other fine chemicals. Due to its reactivity and specificity in certain chemical reactions, 1,1-CyclopropanediMethanol diMethanesulfonate is an important compound in organic chemistry.

Upstream product

• 6914-71-2 dimethyl 1,1-cyclopropanedicarboxylate 
• 598-10-7 cyclopropane-1,1-dicarboxylic acid 
• 39590-81-3 [1-(hydroxymethyl)cyclopropyl]methanol 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 3849-07-8 1-<(4-methylbenzenesulfonyl)oxy>cyclobutanemethanol 4-methylbenzenesulfonate 
• 148420-02-4 2-methylene-1,4-butanediol dimethanesulfonate 
• 148420-03-5 2-methylene-1,4-butanediol bis(4-methylbenzenesulfonate) 
• 1441670-89-8 (6S)-6-[5-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]heptane-5-carboxylic acid 1,1-dimethylethyl ester 
• 1499193-61-1 (S)-6-(2-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-2-oxoethyl) 5-tert-butyl 5-azaspiro[2.4]heptane-5,6-dicarboxylate 
• 1454843-77-6 (±)-5-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptane-6-carboxylic acid 
• 83321-23-7 1,1-bis(iodomethyl)cyclopropane 
• 1129634-44-1 (6S)-5-[(tert-butoxy)carbonyl]-5-azaspiro[2.4]heptane-6-carboxylic acid 
• 1354623-70-3 5,8-dibenzyl-7-methyl-5,8-diazaspiro[2.6]nonane 
• 1354623-80-5 2-[2-oxo-2-[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.6]nonan-8-yl]ethyl]benzonitrile 
• 1354623-77-0 N-[4-(5-benzyl-5,8-diazaspiro[2.6]nonan-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]pentanamide 
• 1354623-74-7 4-(5-benzyl-5,8-diazaspiro[2.6]nonan-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 1354623-59-8 5-benzyl-8-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.6]nonane 
• 1354623-58-7 5-benzyl-5,8-diazaspiro[2.6]nonane 

Relevant articles and documents

A Spiroalkylation Method for the Stereoselective Construction of α-Quaternary Carbons and Its Application to the Total Synthesis of (R)-Puraquinonic Acid

Cyclic α-quaternary carbon stereocenters were prepared from biselectrophillic substrates and an easily prepared chiral bicyclic sulfonyl lactam. This was achieved in two steps by spiroalkylation, employing biphasic reaction conditions with a phase-transfer catalyst, followed by reduction and alkylation with a series of alkyl halide electrophiles. The products of this method were isolated in good yields with with high levels of diastereoselectivity. This methodology was employed in the enantioselective total synthesis of (R)-puraquinonic acid (1) for a late-stage installation of the α-quaternary carbon stereocenter. This enabled the shortest synthesis of 1 to date, an eight-pot sequence providing an overall yield of 14%.

NOVEL COMPOUNDS FOR MODULATION OF ROR-GAMMA ACTIVITY

The present invention relates to aryl sulfones and related compounds that are modulators of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these modulators, and methods of modulating ROR-gamma receptors using them. Also provided are methods of using aryl sulfones and related compounds as modulators of ROR-gamma to treat ROR-gamma mediated diseases